Eden sells Zepbound for $1,399. Lilly sells it for $299.

Same molecule. Same manufacturer. Same box. Four to eleven times the price, depending on where you click.

The numbers

This is not a subtle finding and it does not require interpretation.

Is this a scam?

No — and it is important to be precise, because the truth is more useful than an accusation.

These prices are disclosed. The platforms are not hiding them. What they are relying on is that a patient arriving at a telehealth site does not know that LillyDirect and NovoCare exist, or that a manufacturer will sell to them directly at a fraction of the price.

A patient who does not know that can pay $1,399 for a drug available at $299. The information gap does the work. Nothing false has to be said.

The Mounjaro version of the same trap

Mounjaro and Zepbound are the same molecule — tirzepatide. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for weight management.

Lilly runs a self-pay programme for Zepbound and none for Mounjaro. So cash-pay Mounjaro sits at retail: $1,899 at Hers, roughly $1,100 at Found and PlushCare. Brand Zepbound through LillyDirect is $299-$449 for the identical drug.

The one rule

Before you buy any brand-name GLP-1 through any telehealth platform, check LillyDirect and NovoCare first.

That is the whole article. It takes ninety seconds and it is worth, in the worst case, more than $1,000 a month.

A platform can still be worth paying for. WeightWatchers Clinic charges $74 a month on top of LillyDirect-equivalent drug pricing and manages the 45-day refill window for you — if you cannot reliably track that window, $74 is cheap insurance against a $250 penalty. PlushCare's $19.99 buys prior-authorisation support that can save you far more. Those are services with prices attached. A $1,100 markup on the drug itself is not.

Limitations of this analysis

Every page on this site should tell you where it stops being reliable. This one stops here.

Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.

Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.

We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.

Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.

We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.

Update history